Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.435
-0.045 (-3.04%)
At close: Apr 28, 2026, 4:00 PM EDT
1.440
+0.005 (0.35%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Metagenomi Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Metagenomi Therapeutics stock have an average target of 10, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 596.86% from the current stock price of 1.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 19, 2025.
Analyst Ratings
The average analyst rating for Metagenomi Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +387.80% | Aug 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +666.55% | Aug 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +736.24% | Aug 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +736.24% | May 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $20 → $16 | Buy | Maintains | $20 → $16 | +1,014.98% | May 14, 2025 |
Financial Forecast
Revenue This Year
23.91M
from 25.21M
Decreased by -5.15%
Revenue Next Year
23.00M
from 23.91M
Decreased by -3.80%
EPS This Year
-2.14
from -2.36
EPS Next Year
-1.92
from -2.14
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 42.0M | 42.0M | ||||||
| Avg | 23.9M | 23.0M | ||||||
| Low | 15.7M | 14.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 66.6% | 75.6% | ||||||
| Avg | -5.1% | -3.8% | ||||||
| Low | -37.8% | -38.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.05 | -0.96 | ||||||
| Avg | -2.14 | -1.92 | ||||||
| Low | -2.24 | -2.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.